Page 40 - BH-1-2

Brain & Heart Autonomic nerve and heart failure

https://doi.org/10.1371/journal.pone.0072691 study report. J Hypertens, 35: 2532–2536.
59. Liske H, Towne C, Anikeeva P, et al., 2013, Optical inhibition https://doi.org/10.1097/HJH.0000000000001498
of motor nerve and muscle activity in vivo. Muscle Nerve,
47: 916–921. 70. Ambrosioni E, Bacchelli S, Esposti DD, et al., 2001, Beta-
blockade in hypertension and congestive heart failure.
https://doi.org/10.1002/mus.23696 J Cardiovasc Pharmacol, 38 Suppl 3: S25–S31.
60. Iyer SM, Vesuna S, Ramakrishnan C, et al., 2016, Optogenetic https://doi.org/10.1097/00005344-200112003-00005
and chemogenetic strategies for sustained inhibition of pain.
Sci Rep, 6: 30570. 71. Writing Committee Members, Yancy CW, Jessup M, et al.,
2013, 2013 ACCF/AHA guideline for the management
https://doi.org/10.1038/srep30570 of heart failure: A report of the American College of
61. Hudry E, Vandenberghe LH, 2019, Therapeutic AAV gene Cardiology Foundation/American Heart Association Task
transfer to the nervous system: A clinical reality. Neuron, Force on Practice Guidelines. Circulation, 128: e240–e327.
101: 839–862. https://doi.org/10.1161/CIR.0b013e31829e877
https://doi.org/10.1016/j.neuron.2019.02.017 72. Rienstra M, Damman K, Mulder BA, et al., 2013, Beta-
62. Naso MF, Tomkowicz B, Perry WL 3 , et al., 2017, Adeno- blockers and outcome in heart failure and atrial fibrillation:
rd
associated virus (AAV) as a vector for gene therapy. A meta-analysis. JACC Heart Fail, 1: 21–28.
BioDrugs, 31: 317–334. https://doi.org/10.1016/j.jchf.2012.09.002
https://doi.org/10.1007/s40259-017-0234-5 73. McMurray JJ, Adamopoulos S, Anker SD, et al., 2012, ESC
63. Rodrigues GA, Shalaev E, Karami TK, et al., 2019, guidelines for the diagnosis and treatment of acute and
Pharmaceutical development of AAV-based gene therapy chronic heart failure 2012: The task force for the diagnosis
products for the eye. Pharm Res, 36: 29. and treatment of acute and chronic heart failure 2012 of the
European Society of Cardiology. Developed in collaboration
https://doi.org/10.1007/s11095-018-2554-7
with the Heart Failure Association (HFA) of the ESC. Eur J
64. Fontaine AK, Futia GL, Rajendran PS, et al., 2021, Optical Heart Fail, 33: 803–869.
vagus nerve modulation of heart and respiration via heart- https://doi.org/10.1093/eurheartj/ehs104
injected retrograde AAV. Sci Rep, 11: 3664.
74. Brophy JM, Joseph L, Rouleau JL, 2001, Beta-blockers in
https://doi.org/10.1038/s41598-021-83280-3
congestive heart failure. A Bayesian meta-analysis. Ann
65. Bates MC, Stone GW, Chen CY, et al., 2020, Device profile of Intern Med, 134: 550–560.
the MobiusHD EVBA system for the treatment of resistant
hypertension: Overview of its mechanism of action, safety https://doi.org/10.7326/0003-4819-134-7-200104030-00008
and efficacy. Expert Rev Med Devices, 17: 649–658. 75. Chidsey CA, Harrison DC, Braunwald E, 1962,
https://doi.org/10.1080/17434440.2020.1779054 Augmentation of the plasma nor-epinephrine response to
exercise in patients with congestive heart failure. N Engl J
66. Olsson L, Swedberg GS, Clark AL, et al., 2005, Six minute Med, 267: 650–654.
corridor walk test as an outcome measure for the assessment
of treatment in randomized, blinded intervention trials https://doi.org/10.1056/NEJM196209272671305
of chronic heart failure: A systematic review. Eur Heart J, 76. Phan TT, Shivu GN, Abozguia K, et al., 2010, Impaired heart
26: 778–793. rate recovery and chronotropic incompetence in patients
https://doi.org/10.1093/eurheartj/ehi162 with heart failure with preserved ejection fraction. Circ
Heart Fail, 3: 29–34.
67. Cleland JG, Daubert JC, Erdmann E, et al., 2005, The effect
of cardiac resynchronization on morbidity and mortality in https://doi.org/10.1161/CIRCHEARTFAILURE.109.877720
heart failure. N Engl J Med, 352: 1539–1549. 77. Ueda T, Kawakami R, Nishida T, et al., 2015, Left ventricular
https://doi.org/10.1056/NEJMoa050496 ejection fraction (EF) of 55% as cutoff for late transition
from heart failure (HF) with preserved EF to HF with mildly
68. Gronda E, Seravalle G, Trevano FQ, et al., 2015, Long-term reduced EF. Circ J, 79: 2209–2215.
chronic baroreflex activation: Persistent efficacy in patients
with heart failure and reduced ejection fraction. J Hypertens, https://doi.org/10.1253/circj.CJ-15-0425
33: 1704–1708. 78. Borlaug BA, Melenovsky V, Russell SD, et al., 2006, Impaired
https://doi.org/10.1097/HJH.0000000000000603 chronotropic and vasodilator reserves limit exercise capacity
in patients with heart failure and a preserved ejection
69. Dell’Oro R, Gronda E, Seravalle G, et al., 2017, Restoration
of normal sympathetic neural function in heart failure fraction. Circulation, 114: 2138–2147.
following baroreflex activation therapy: Final 43-month https://doi.org/10.1161/CIRCULATIONAHA.106.632745

Volume 1 Issue 2 (2023) 11 https://doi.org/10.36922/bh.0913